David C. Sachs - 22 Feb 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: IBRX
Reported as of: 22 Feb 2026
Net transaction value: -$179,933
SEC form: 4
Accepted by SEC: 24 Feb 2026, 20:05:12 UTC
Prior SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Philip LoScalzo, as Attorney-in-Fact

Key filing fact

David C. Sachs filed Form 4 for ImmunityBio, Inc. (IBRX) on 24 Feb 2026.

Key facts

This page summarizes David C. Sachs's Form 4 filing for ImmunityBio, Inc. (IBRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 20:05.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: -$179,933.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001848899 Primary reporting owner

Sachs David C.

Relationship: Chief Financial Officer
Address: C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature: /s/ Philip LoScalzo, as Attorney-in-Fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBRX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +40,650
Change %: +15%
Price: $0.000000
Shares after: 320,825
Date: 22 Feb 2026
Ownership: Direct
Footnotes: F1

IBRX transaction

Common Stock

Tax liability

Transaction value: $179,933
Shares: -20,682
Change %: -6.4%
Price: $8.70
Shares after: 300,143
Date: 22 Feb 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -40,650
Change %: -50%
Price: $0.000000
Shares after: 40,651
Date: 22 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,650
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

Footnote F2

On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

Footnote F3

Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.